此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial

2019年3月7日 更新者:National Taiwan University Hospital

A Single-Blind Randomized Trial of Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Locally Advanced Non-Small Cell and Small Cell Lung Cancer

Thoracic radiotherapy (TRT) is a standard curative treatment for locally advanced, unresectable non-small cell lung cancer (NSCLC) and limited stage small cell lung cancer (SCLC). TRT has been recognized to cause moderate to severe lung injury in a substantial portion of patients. Conventional standard curative TRT planning techniques minimize the radiation dose to the anatomical lungs, without adaption of regional pulmonary function variations. The principal investigator hypothesized that preferential avoidance of functional lung during curative TRT may decrease the risk of pulmonary toxicity. Functional lung regions are identified using four- dimensional computed tomography for ventilation imaging. This randomized, single-blind trial will comprehensively assess the impact of functional lung avoidance on pulmonary toxicity, quality of life, and clinical outcome in patients receiving curative TRT for locally advanced NSCLC and SCLC.

研究概览

研究类型

介入性

注册 (预期的)

64

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Taipei、台湾、100
        • 招聘中
        • National Taiwan University Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion criteria:

  1. Patients with a histologic diagnosis of non-small cell carcinoma or small cell carcinoma of lung
  2. Locally advanced stage III A or III B lung carcinoma according to American Joint Committee on Cancer (AJCC) 7th edition or highly selected patients with oligo-metastatic disease amendable for thoracic radiotherapy with curative intent
  3. Not undergoing radical surgical resection
  4. Patients do not have prior radiotherapy to the thorax
  5. Age ≥ 20 years
  6. Karnofsky performance status (KPS) ≥ 60%.
  7. Women of childbearing potential and male participants must practice adequate contraception
  8. Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific informed consent

Exclusion criteria:

  1. Prior radiotherapy to thorax
  2. Unable to receive assigned radiation dose due to normal lung constraint
  3. Inability to attend full course of radiotherapy or follow-up visits
  4. Presence of metastatic disease. Patients who present with oligo-metastatic disease where all metastases have been ablated (with surgery or radiotherapy) or in complete remission after systemic therapy are candidates if they are receiving radiotherapy to the thoracic disease with curative intent
  5. Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:

    • Uncontrolled active infection requiring intravenous antibiotics at the time of registration
    • Transmural myocardial infarction ≤ 6 months prior to registration.
    • Unstable angina or congestive heart failure requiring hospitalization ≤ 6 months prior to registration.
    • Life-threatening uncontrolled clinically significant cardiac arrhythmias.
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
    • Uncontrolled psychiatric disorder.
  6. Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic.
  7. Pregnant or lactating women

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Functional Lung Avoidance-TRT

Functional Lung Avoidance Thoracic Radiotherapy

The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable

  • Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)
  • Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)
  • Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions
有源比较器:Standard-TRT

Standard Thoracic Radiotherapy

The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging

  • Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)
  • Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)
  • Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The pulmonary quality of life at 3 months post-radiotherapy
大体时间:Change from Baseline Functional Assessment of Cancer Therapy-Lung Cancer Subscale at 3 months
Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS)
Change from Baseline Functional Assessment of Cancer Therapy-Lung Cancer Subscale at 3 months

次要结果测量

结果测量
措施说明
大体时间
总生存期
大体时间:从入组之日起至因任何原因死亡之日,评估最长 60 个月
活着的参加者人数
从入组之日起至因任何原因死亡之日,评估最长 60 个月
Changes of pulmonary function test post-radiotherapy
大体时间:At baseline, 3, 6, 12 months, and annually until year 5 post-radiotherapy
Screening spirometry, diffusion capacity of lung for carbon monoxide
At baseline, 3, 6, 12 months, and annually until year 5 post-radiotherapy
Patient reported outcome (Quality of Life questionnaire by Functional Assessment of Cancer Therapy)
大体时间:At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
Functional Assessment of Cancer Therapy-Lung
At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
Patient reported outcome (Quality of Life questionnaire by EORTC Core)
大体时间:At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
EORTC Quality of Life-Core 30 questionnaire module
At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
Patient reported outcome (Quality of Life questionnaire by EORTC Lung cancer)
大体时间:At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
EORTC Quality of Life questionnaire -Lung cancer 13
At baseline, 1, 2, 3, 4, 6, 9 12 months post-radiotherapy
Acute toxicity
大体时间:From date of radiotherapy until 90 days after radiotherapy starts
Common Toxicity Criteria for Adverse Events version 4
From date of radiotherapy until 90 days after radiotherapy starts
Late toxicity
大体时间:90 days after radiotherapy starts until the date of death from any cause, up to 60 months
Common Toxicity Criteria for Adverse Events version 4
90 days after radiotherapy starts until the date of death from any cause, up to 60 months
Progression free survival
大体时间:From date of enrollment until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 60 months
Number of participant without disease progression
From date of enrollment until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 60 months

其他结果措施

结果测量
措施说明
大体时间
Serum biomarkers in association with radiation pneumonitis
大体时间:At baseline, 1, 2, 3, 4, 6 months post-radiotherapy
Tumor necrosis factor-alpha, Transforming growth factor-beta concentration measured by ELISA
At baseline, 1, 2, 3, 4, 6 months post-radiotherapy

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2016年6月1日

初级完成 (预期的)

2021年5月1日

研究完成 (预期的)

2023年5月1日

研究注册日期

首次提交

2016年6月27日

首先提交符合 QC 标准的

2017年3月7日

首次发布 (实际的)

2017年3月13日

研究记录更新

最后更新发布 (实际的)

2019年3月11日

上次提交的符合 QC 标准的更新

2019年3月7日

最后验证

2019年3月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅